Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1708842 | 1.00 | CYP2D6 (0.32) | CYP2D6KCNH2HRH3 | |
| SCHEMBL10267353 | 1.00 | CYP2D6 (0.32) | CYP2D6KCNH2HRH3 | |
| SCHEMBL18327050 | 0.86 | — | — | |
| SCHEMBL2601347 | 0.86 | — | — | |
| SCHEMBL2614325 | 0.86 | — | — | |
| SCHEMBL2706991 | 0.84 | CYP2D6 (0.38) | CYP2D6KCNH2HRH3 | |
| SCHEMBL21969664 | 0.84 | — | — | |
| SCHEMBL17545823 | 0.84 | — | — | |
| SCHEMBL19788693 | 0.83 | — | — | |
| SCHEMBL23594101 | 0.81 | CYP2D6 (0.31) | CYP2D6KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227471-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230212170-A1 | INHIBITORS OF KRAS G12C PROTEIN AND USES THEREOF | ANTENGENE DISCOVERY LIMITED (CN) | 2023-07-06 | — | — | US | disclosed |
| US-20210038749-A1 | FAP INHIBITOR | Universität Heidelberg (DE) | 2021-02-11 | — | — | US | disclosed |
| US-10683278-B2 | Substituted quinolone derivatives, or pharmaceutically acceptable salts or stereoisomers thereof, and pharmaceutical compositions and use thereof | SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) | 2020-06-16 | — | — | US | disclosed |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210038749-A1 | FAP INHIBITOR | FAP, APC, FIBP | CYP2D6 3465/4885KCNH2 3314/4885HRH3 3752/4885 |
| US-10683278-B2 | Substituted quinolone derivatives, or pharmaceutically acceptable salts or stereoisomers thereof, and pharmaceutical compositions and use thereof | NRAS, AXL, ABL1 | CYP2D6 1150/4885KCNH2 4702/4885HRH3 3702/4885 |
| US-20230212170-A1 | INHIBITORS OF KRAS G12C PROTEIN AND USES THEREOF | KRAS, NRAS, HRAS | CYP2D6 4317/4885KCNH2 4765/4885HRH3 2927/4885 |
| US-20230227471-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | BTK, CBL, XIAP | CYP2D6 3589/4885KCNH2 4713/4885HRH3 3674/4885 |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | REN, SERPINB1, MME | CYP2D6 3204/4885KCNH2 1801/4885HRH3 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.